TY - JOUR T1 - Violin plot data: A concerto of crucial information on valve thrombogenicity classified using laboratory measured valve motion JF - medRxiv DO - 10.1101/19009407 SP - 19009407 AU - Lawrence N. Scotten AU - David Blundon AU - Marcus-André Deutsch AU - Rolland Siegel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/25/19009407.abstract N2 - Objectives We hypothesize that prosthetic valve thrombogenic potential may be inferred by valve regional flow velocity. This metric was used to compare two clinical valves and two experimental prototypes.Methods Four our clinical and experimental prototype valve models were tested in aortic and mitral sites under pulsatile circulation in a pulse duplicator. An optical approach measuring projected dynamic valve area to gauge valve motion was implemented. Pulsatile pressures and flow rates were measured by conventional techniques and a quasi-steady flow tester was used to measure valve leakage. Regurgitant flow velocity was derived using time-dependent volumetric flow rate / projected dynamic valve area. Since flow velocity and fluid shear force are related through flow velocity gradient, thrombogenic potential for valves that achieve near closure during the forward flow deceleration phase were determined as regurgitant flow velocities relative to the control mechanical valve regurgitant flow velocity of −126 m/s. Analysis of the flow velocity data made use of Vioplot R* and VISIO software packages to provide split violin plots that represent probability of recurrence of data.Results Thrombogenic potential was made dimensionless and ranged between −0.45 and +1.0. Negative thrombogenic potentials arise when transient rebound of valve occluder is accompanied by water-hammer phenomena. Positive thrombogenic potentials occur during decelerating forward flow. Bioprostheses had lowest thrombogenic potential transient of 0.15. A mock-transcatheter aortic valve replacement incorporating by design a trivial paravalvular leak (∼1.35 ml/s) demonstrated a high transient thrombogenic potential of 0.95.Conclusions Our data reveals distinct thrombogenic potential profile differences between valve models. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.Central Message Valve motion and flow velocity contribute to valve thrombogenic potential (TP) as revealed by closure-related functional deficit common to current mechanical heart valves (MHVs). Appreciation of valve closure is crucial to design of advanced valves with TP comparable to tissue valves and is achievable with current technology. Consistent with recent clinical experience, data from our mock transcatheter aortic valve replacement (mTAVR) device suggests modifications to commercial TAVR prostheses to reduce PVL results in smaller paravalvular leaks (PVLs) with greater TP. A consequential outcome of our work is development of a practical laboratory method for screening prototype valves for TP compared with well established clinical controls.Perspective Nearly 60 years after their introduction, modifications to mechanical and bioprosthetic valves have not yet resolved chronic shortcomings related to durability and thrombogenic potential. In prior publications, we hypothesized that mechanical valve occluder closing behavior was conspicuously implicated in the thrombogenic discrepancy between mechanical and bioprosthetic valves and this was evidenced in laboratory experiments by assessment of valve flow velocity. Although computational methods employed to examine contemporary mechanical and bioprosthetic valve function have generated extensive information on device fluid dynamics, a development pathway has not yet been proposed to eliminate thrombogenicity in the former and extend durability in the latter. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been done on a pro bono basis by all authors with no financial support of others.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableAll data relevant to the study are included in the article or uploaded as supplementary information.BHVbioprosthetic heart valveBV3Dprototype bileaflet valve (rapid 3D printed)cmcentimeterdp/dtrate of change of pressure with time (mmHg/s)dyne/cm2shear stress (force/area)HITShigh intensity trancranial signalLDHlactate dehydrogenaseml/smilliliters per secondm/smeters per secondmmHgmillimeters of mercurymTAVRmock transcatheter aortic valve replacementMHVmechanical heart valvePDVAprojected dynamic valve areaPVLparavalvular leakageRFVregurgitant flow velocityssecondSJMSt Jude MedicalTADtissue annulus diameterTAVRtranscatheter aortic valve replacementTPthrombogenic potentialTPIthrombogenic potential indexU/LU/L International unit of LDH defined as the amount of enzyme that catalyzes the conversion of 1 µmol of substrate per minute under specified conditions.µmolSI unit of amount of substance equal to 10−6 molesµsmicrosecondVIAviscoelastic impedance adapter ER -